Medical Cannabis Not Recommended for Sleep Apnea

Share this content:
Medical Cannabis Not Recommended for Sleep Apnea
Medical Cannabis Not Recommended for Sleep Apnea

FRIDAY, April 20, 2018 (HealthDay News) -- Medical cannabis and/or its synthetic extracts should not be used for treating patients with obstructive sleep apnea (OSA), according to an American Academy of Sleep Medicine position statement published in the April 15 issue of the Journal of Clinical Sleep Medicine.

Noting that limited evidence suggests that the synthetic medical cannabis extract dronabinol may be beneficial in OSA, Kannan Ramar, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues explored its use.

The researchers write that side effects associated with dronabinol treatment, including somnolence, were reported in most patients, while long-term effects on sleep quality measures, safety, and tolerability are unknown. Dronabinol has not been approved by the U.S. Food and Drug Administration as a treatment for OSA; medical cannabis and other synthetic extracts have not been assessed for OSA. Within medical cannabis, the composition of cannabinoids varies significantly, with no regulation. Due to unreliable delivery methods and insufficient evidence on effectiveness, tolerability, and safety, the American Academy of Sleep Medicine concludes that medical cannabis and/or its synthetic extracts should not be used for OSA treatment.

"OSA should be excluded from the list of chronic medical conditions for state medical cannabis programs, and patients with OSA should discuss their treatment options with a licensed medical provider at an accredited sleep facility," the authors write. "Further research is needed to understand the functionality of medical cannabis extracts before recommending them as a treatment for OSA."

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »